Anti-TNF alfa therapy in ankylosing spondylitis.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916 |
Resumo: | Ankylosing spondylitis (AS) is an inflammatory chronic disease that affects young males and in more than 90% of cases is associated with HLA B27 antigen. Therapeutic options for those patients with spondyloarthropathies have been limited during the last decades. Infliximab and etanercept are both approved for the treatment of patients with active disease that does not respond to conventional therapies. Anti-TNF therapy is very effective in AS, and eventually can be more effective than in rheumatoid arthritis. In 2003 Assessments in Ankylosing Spondylitis Group (ASAS) published international recommendations about the use of these agents in AS, which can be used as guidance in taking decisions and elaborating guidelines. To define their utilization it is necessary more studies about efficacy, toxicity and about ways of use. |
id |
RCAP_f3a49496f5b7a4daf239e020272c4946 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/916 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Anti-TNF alfa therapy in ankylosing spondylitis.Terapêutica anti-TNF alfa na espondilite anquilosante.Ankylosing spondylitis (AS) is an inflammatory chronic disease that affects young males and in more than 90% of cases is associated with HLA B27 antigen. Therapeutic options for those patients with spondyloarthropathies have been limited during the last decades. Infliximab and etanercept are both approved for the treatment of patients with active disease that does not respond to conventional therapies. Anti-TNF therapy is very effective in AS, and eventually can be more effective than in rheumatoid arthritis. In 2003 Assessments in Ankylosing Spondylitis Group (ASAS) published international recommendations about the use of these agents in AS, which can be used as guidance in taking decisions and elaborating guidelines. To define their utilization it is necessary more studies about efficacy, toxicity and about ways of use.Ankylosing spondylitis (AS) is an inflammatory chronic disease that affects young males and in more than 90% of cases is associated with HLA B27 antigen. Therapeutic options for those patients with spondyloarthropathies have been limited during the last decades. Infliximab and etanercept are both approved for the treatment of patients with active disease that does not respond to conventional therapies. Anti-TNF therapy is very effective in AS, and eventually can be more effective than in rheumatoid arthritis. In 2003 Assessments in Ankylosing Spondylitis Group (ASAS) published international recommendations about the use of these agents in AS, which can be used as guidance in taking decisions and elaborating guidelines. To define their utilization it is necessary more studies about efficacy, toxicity and about ways of use.Ordem dos Médicos2006-08-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916oai:ojs.www.actamedicaportuguesa.com:article/916Acta Médica Portuguesa; Vol. 19 No. 2 (2006): March-April; 141-50Acta Médica Portuguesa; Vol. 19 N.º 2 (2006): Março-Abril; 141-501646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916/589Cravo, Ana RitaTavares, VivianaDa Silva, José Canasinfo:eu-repo/semantics/openAccess2022-12-20T10:57:09Zoai:ojs.www.actamedicaportuguesa.com:article/916Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:16:51.239470Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Anti-TNF alfa therapy in ankylosing spondylitis. Terapêutica anti-TNF alfa na espondilite anquilosante. |
title |
Anti-TNF alfa therapy in ankylosing spondylitis. |
spellingShingle |
Anti-TNF alfa therapy in ankylosing spondylitis. Cravo, Ana Rita |
title_short |
Anti-TNF alfa therapy in ankylosing spondylitis. |
title_full |
Anti-TNF alfa therapy in ankylosing spondylitis. |
title_fullStr |
Anti-TNF alfa therapy in ankylosing spondylitis. |
title_full_unstemmed |
Anti-TNF alfa therapy in ankylosing spondylitis. |
title_sort |
Anti-TNF alfa therapy in ankylosing spondylitis. |
author |
Cravo, Ana Rita |
author_facet |
Cravo, Ana Rita Tavares, Viviana Da Silva, José Canas |
author_role |
author |
author2 |
Tavares, Viviana Da Silva, José Canas |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Cravo, Ana Rita Tavares, Viviana Da Silva, José Canas |
description |
Ankylosing spondylitis (AS) is an inflammatory chronic disease that affects young males and in more than 90% of cases is associated with HLA B27 antigen. Therapeutic options for those patients with spondyloarthropathies have been limited during the last decades. Infliximab and etanercept are both approved for the treatment of patients with active disease that does not respond to conventional therapies. Anti-TNF therapy is very effective in AS, and eventually can be more effective than in rheumatoid arthritis. In 2003 Assessments in Ankylosing Spondylitis Group (ASAS) published international recommendations about the use of these agents in AS, which can be used as guidance in taking decisions and elaborating guidelines. To define their utilization it is necessary more studies about efficacy, toxicity and about ways of use. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-08-18 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916 oai:ojs.www.actamedicaportuguesa.com:article/916 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/916 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916/589 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 19 No. 2 (2006): March-April; 141-50 Acta Médica Portuguesa; Vol. 19 N.º 2 (2006): Março-Abril; 141-50 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130622291083264 |